烧伤手术中的局部止血剂:一项系统综述
该系统综述检索了PubMed、Scopus和Web of Science从最早收录至2021年9月10日的文献,最终纳入49项研究,评估烧伤切除和/或植皮手术中局部止血剂的使用情况。最常用的血管收缩剂为肾上腺素(剂量1:1000至1:1,000,000),最常用的促凝血剂为凝血酶(剂量10至1000 IU/ml)。94%的研究证据等级为III-V级,由于失血量报告不一致而无法进行Meta分析。
要点
- 纳入49项研究,32项使用血管收缩剂,28项使用促凝血剂,4项使用其他制剂。
- 肾上腺素剂量范围为1:1000至1:1,000,000,凝血酶剂量范围为10至1000 IU/ml。
- 94%的研究证据等级为III-V级,失血量报告不一致,无法进行Meta分析。
核心结论
- 确定最佳局部止血剂受限于低质量数据和术中失血量报告不一致的问题。
- 鉴于局部止血剂在烧伤手术中的常规使用,需要高质量研究来确定最佳制剂、剂量和给药方式。
研究设计与样本
- 由两名独立评价者进行的系统综述,检索PubMed、Scopus和Web of Science从最早收录至2021年9月10日的文献。
- 纳入标准为英文发表且描述或评估烧伤切除和/或植皮手术中使用的局部止血剂的研究。
- 检索识别1982条非重复引用,其中134篇进行全文审查,49篇符合纳入标准。
主要发现
- 32项研究使用了血管收缩剂,28项研究使用了促凝血剂,4项研究使用了其他制剂(过氧化氢、氨甲环酸、胶原片和TT-173)。
- 最常用的血管收缩剂为肾上腺素,剂量范围为1:1000至1:1,000,000。
- 最常用的促凝血剂为凝血酶,剂量范围为10至1000 IU/ml。
- 在比较性研究中,失血量结局的报告方式不一致,因此无法进行Meta分析。
- 大多数研究(94%)的证据等级为III-V级。
局限性
- 确定最佳局部止血剂受限于低质量数据。
- 术中失血量报告方式不一致导致无法进行Meta分析。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Acute burn surgery has long been associated with significant intra-operative bleeding. Several techniques were introduced to limit hemorrhage, including tourniquets, tumescent infiltration, and topical agents. To date, no study has comprehensively investigated the available data regarding topical hemostatic agents in burn surgery. A systematic review was performed by two independent reviewers using electronic databases (PubMed, Scopus, Web of Science) from first available to September 10, 2021. Articles were included if they were published in English and described or evaluated topical hemostatic agents used in burn excision and/or grafting. Data were extracted on the agent(s) used, their dosage, mode of delivery, hemostasis outcomes, and complications. The search identified 1982 nonduplicate citations, of which 134 underwent full-text review, and 49 met inclusion criteria. In total, 32 studies incorporated a vasoconstrictor agent, and 28 studies incorporated a procoagulant agent. Four studies incorporated other agents (hydrogen peroxide, tranexamic acid, collagen sheets, and TT-173). The most common vasoconstrictor used was epinephrine, with doses ranging from 1:1000 to 1:1,000,000. The most common procoagulant used was thrombin, with doses ranging from 10 to 1000 IU/ml. Among the comparative studies, outcomes of blood loss were not reported in a consistent manner, therefore meta-analysis could not be performed. The majority of studies (94%) were level of evidence III-V. Determining the optimal topical hemostatic agent is limited by low-quality data and challenges with consistent reporting of intra-operative blood loss. Given the routine use of topical hemostatic agents in burn surgery, high-quality research is essential to determine the optimal agent, dosage, and mode of delivery.
引用
- Battistini A, Gottlieb LJ, Vrouwe SQ, et al. Topical Hemostatic Agents in Burn Surgery: A Systematic Review. J Burn Care Res. 2023. PMID: 36516423. doi:10.1093/jbcr/irac185
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。